Official Title
Long-term Large Sample Multicenter Follow-up Study of COVID-19
Brief Summary

The goal of this observational study is to learn the long-term prognosis of patients andthe clinical characteristics of complications, which is of great significance fortreatment of novel coronavirus infection pneumonia.This trial plans to include 5700 inpatients with positive SARS CoV-2 nucleic acid testresults. This trial does not involve the use of specific drug. Participants's health andpsychological status will be observed at the preset time points. The blood, feces, urinesamples of patients will be collected for relevant tests.

Detailed Description

After the patients are enrolled, record the patient's treatment regimens, blood routine
results, blood biochemistry results, cytokines results, lung imaging results, and cranial
imaging results, understand the patient's current clinical manifestations, evaluate the
patient's psychological status and quality of life, and collect samples of the patients'
blood, feces, urine, and other related tests.

Collection of clinical samples: collect blood, urine, throat swabs and other samples from
patients with confirmed novel coronavirus pneumonia (Nucleic acid test positive), and
collect samples for relevant tests at 3 months, 6 months, 12 months, 18 months, 24 months
and 36 months after discharge of patients, and record the clinical manifestations of
patients.

Recruiting
COVID-19
Eligibility Criteria

Inclusion Criteria:

- Patients with confirmed COVID-19

Exclusion Criteria:

- Combined infection with influenza virus, mycoplasma, and chlamydia.

Eligibility Gender
All
Eligibility Age
Minimum: 18 Years ~ Maximum: N/A
Countries
China
Locations

Tongji Hospital affiliated to Tongji Medical College of Huazhong University of Science & Technology
Wuhan, Hu Bei Province, China

Wuhan Seventh Hospital
Wuhan, Hu Bei Province, China

Contacts

Qin Ning, Professor
+8613971521450
qning@vip.sina.com

Qin Ning, Professor, Principal Investigator
Tongji Hospital

Tongji Hospital
NCT Number
MeSH Terms
COVID-19